JPWO2021243415A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021243415A5 JPWO2021243415A5 JP2022574600A JP2022574600A JPWO2021243415A5 JP WO2021243415 A5 JPWO2021243415 A5 JP WO2021243415A5 JP 2022574600 A JP2022574600 A JP 2022574600A JP 2022574600 A JP2022574600 A JP 2022574600A JP WO2021243415 A5 JPWO2021243415 A5 JP WO2021243415A5
- Authority
- JP
- Japan
- Prior art keywords
- conjugate
- targeting agent
- group
- cancer
- dendrimer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 claims description 43
- 230000008685 targeting Effects 0.000 claims description 41
- 239000000412 dendrimer Substances 0.000 claims description 20
- 229920000736 dendritic polymer Polymers 0.000 claims description 20
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 239000002202 Polyethylene glycol Substances 0.000 claims description 10
- 229920001223 polyethylene glycol Polymers 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 125000000539 amino acid group Chemical group 0.000 claims description 8
- 230000000536 complexating effect Effects 0.000 claims description 8
- 125000006850 spacer group Chemical group 0.000 claims description 8
- 125000000524 functional group Chemical group 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 125000002355 alkine group Chemical group 0.000 claims description 4
- 229920006187 aquazol Polymers 0.000 claims description 4
- 150000003384 small molecules Chemical group 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 claims description 3
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 229910052765 Lutetium Inorganic materials 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 3
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 229910052733 gallium Inorganic materials 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- OHSVLFRHMCKCQY-UHFFFAOYSA-N lutetium atom Chemical compound [Lu] OHSVLFRHMCKCQY-UHFFFAOYSA-N 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 229910052726 zirconium Inorganic materials 0.000 claims description 3
- SOAPXKSPJAZNGO-WDSKDSINSA-N (2s)-2-[[(1s)-1,3-dicarboxypropyl]carbamoylamino]pentanedioic acid Chemical class OC(=O)CC[C@@H](C(O)=O)NC(=O)N[C@H](C(O)=O)CCC(O)=O SOAPXKSPJAZNGO-WDSKDSINSA-N 0.000 claims description 2
- NEMHIKRLROONTL-QMMMGPOBSA-N (2s)-2-azaniumyl-3-(4-azidophenyl)propanoate Chemical group OC(=O)[C@@H](N)CC1=CC=C(N=[N+]=[N-])C=C1 NEMHIKRLROONTL-QMMMGPOBSA-N 0.000 claims description 2
- JHALWMSZGCVVEM-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1 JHALWMSZGCVVEM-UHFFFAOYSA-N 0.000 claims description 2
- GTACSIONMHMRPD-UHFFFAOYSA-N 2-[4-[2-(benzenesulfonamido)ethylsulfanyl]-2,6-difluorophenoxy]acetamide Chemical compound C1=C(F)C(OCC(=O)N)=C(F)C=C1SCCNS(=O)(=O)C1=CC=CC=C1 GTACSIONMHMRPD-UHFFFAOYSA-N 0.000 claims description 2
- WXFIFTYQCGZRGR-UHFFFAOYSA-N 5-hydroxy-2-methylhex-2-enamide Chemical compound CC(O)CC=C(C)C(N)=O WXFIFTYQCGZRGR-UHFFFAOYSA-N 0.000 claims description 2
- 101710130081 Aspergillopepsin-1 Proteins 0.000 claims description 2
- ZUHQCDZJPTXVCU-UHFFFAOYSA-N C1#CCCC2=CC=CC=C2C2=CC=CC=C21 Chemical group C1#CCCC2=CC=CC=C2C2=CC=CC=C21 ZUHQCDZJPTXVCU-UHFFFAOYSA-N 0.000 claims description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- 102100031007 Cytosolic non-specific dipeptidase Human genes 0.000 claims description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims description 2
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 claims description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 2
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims description 2
- 229910052767 actinium Inorganic materials 0.000 claims description 2
- QQINRWTZWGJFDB-UHFFFAOYSA-N actinium atom Chemical compound [Ac] QQINRWTZWGJFDB-UHFFFAOYSA-N 0.000 claims description 2
- 229910052789 astatine Inorganic materials 0.000 claims description 2
- RYXHOMYVWAEKHL-UHFFFAOYSA-N astatine atom Chemical compound [At] RYXHOMYVWAEKHL-UHFFFAOYSA-N 0.000 claims description 2
- -1 benzyl-DOTA Chemical compound 0.000 claims description 2
- 229910052797 bismuth Inorganic materials 0.000 claims description 2
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 239000010949 copper Substances 0.000 claims description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000003384 imaging method Methods 0.000 claims description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 2
- 108010082974 polysarcosine Proteins 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 229910052713 technetium Inorganic materials 0.000 claims description 2
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 229910052727 yttrium Inorganic materials 0.000 claims description 2
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020901833 | 2020-06-03 | ||
| AU2020901833A AU2020901833A0 (en) | 2020-06-03 | Therapeutic conjugates | |
| PCT/AU2021/050554 WO2021243415A1 (en) | 2020-06-03 | 2021-06-03 | Therapeutic conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023529640A JP2023529640A (ja) | 2023-07-11 |
| JPWO2021243415A5 true JPWO2021243415A5 (zh) | 2024-06-10 |
Family
ID=78831413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022574600A Pending JP2023529640A (ja) | 2020-06-03 | 2021-06-03 | 治療用コンジュゲート |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JP2023529640A (zh) |
| KR (1) | KR20230065935A (zh) |
| CN (1) | CN115989039A (zh) |
| AU (1) | AU2021284918A1 (zh) |
| CA (1) | CA3180877A1 (zh) |
| WO (1) | WO2021243415A1 (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023244828A1 (en) * | 2022-06-17 | 2023-12-21 | Purdue Research Foundation | Fibroblast activation protein-targeted nanoparticle magnetic resonance imaging agents |
| WO2024007034A2 (en) * | 2022-07-01 | 2024-01-04 | The Johns Hopkins University | Dendrimer-delivered alpha-particle radiotherapy for treatment of glioblastoma and other cancers in the brain |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2636599C (en) * | 2006-01-20 | 2014-07-15 | Starpharma Pty Limited | Modified macromolecule |
| EP2454271A4 (en) * | 2009-07-15 | 2015-08-12 | Univ California | PEPTIDES WITH CONTROLLABLE CELLULAR RECORDING |
| ES2834992T3 (es) * | 2011-06-06 | 2021-06-21 | Starpharma Pty Ltd | Macromoléculas |
| US20160106856A1 (en) * | 2012-08-14 | 2016-04-21 | Angiochem Inc. | Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin |
| CN113164615A (zh) * | 2018-11-29 | 2021-07-23 | 星法马私人有限公司 | 用于治疗和成像的树状聚体 |
-
2021
- 2021-06-03 CA CA3180877A patent/CA3180877A1/en active Pending
- 2021-06-03 CN CN202180049571.2A patent/CN115989039A/zh active Pending
- 2021-06-03 KR KR1020227046150A patent/KR20230065935A/ko active Search and Examination
- 2021-06-03 AU AU2021284918A patent/AU2021284918A1/en active Pending
- 2021-06-03 WO PCT/AU2021/050554 patent/WO2021243415A1/en unknown
- 2021-06-03 JP JP2022574600A patent/JP2023529640A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Koshkaryev et al. | Immunoconjugates and long circulating systems: origins, current state of the art and future directions | |
| EP1971355B1 (en) | Methods and compositions for delivering active agents with enhanced pharmacological properties | |
| US20240173427A1 (en) | Glypican 3 antibodies and conjugates thereof | |
| JP2019031565A5 (zh) | ||
| JP2017110002A5 (zh) | ||
| JP2008546792A5 (zh) | ||
| JP2004210793A (ja) | 調節された浄化時間を有する修飾抗体 | |
| JP2013518912A5 (zh) | ||
| JP2002543111A (ja) | ポリマーを使用する葉酸で仲介された腫瘍細胞へのターゲッティングの増幅 | |
| JP2008515889A5 (zh) | ||
| US20190298846A1 (en) | Cell targeting conjugates | |
| JP2011505371A5 (zh) | ||
| Sharifi et al. | Improving monoclonal antibody pharmacokinetics via chemical modification | |
| JP2016509586A5 (zh) | ||
| WO2023131219A1 (en) | Conjugates, compositions and methods of use | |
| JPWO2021243415A5 (zh) | ||
| KR20230065935A (ko) | 치료적 접합체 | |
| Bodyak et al. | Delivering more payload (high DAR ADCs) | |
| JP2019513013A5 (zh) | ||
| Fritzberg et al. | Approaches to improved antibody-and peptide-mediated targeting for imaging and therapy of cancer | |
| KR20230010656A (ko) | 금 나노 입자 함유 의약 | |
| CN114746104A (zh) | 治疗由化疗或放疗引起的中性粒细胞减少症的方法 | |
| Shao et al. | Inhibition of human tumor xenograft growth in nude mice by a conjugate of monoclonal antibody LA22 to epidermal growth factor receptor with anti-tumor antibiotics mitomycin C | |
| US20030215387A1 (en) | Bifunctional antibodies and their use in targeting anti-tumour agents | |
| JPWO2020107078A5 (zh) |